Virtual Chromoendoscopy for Colitis Surveillance: A Feasibility Study
- Conditions
- Inflammatory Bowel Disease
- Interventions
- Device: Virtual chromoendoscopyProcedure: Conventional chromoendoscopy
- Registration Number
- NCT02543021
- Lead Sponsor
- King's College Hospital NHS Trust
- Brief Summary
Patients with colitis require regular 'surveillance' colonoscopy as their risk of developing colon cancer is at least 2.5 times that of the general population. However, cancer in colitis develops as flat lesions called dysplasia, that can be easily missed at routine colonoscopy. As a result NICE guidelines for colitis surveillance recommend the use of a technique called chromoendoscopy (CE) in which a water-soluble blue dye is sprayed through the colonoscope to coat and highlight the lining of the bowel, making dysplasia easier to see. Although CE is accepted as best practice for surveillance it is time-consuming, technically difficult and requires expertise to interpret the appearances. For these reasons, its use is not widespread and the vast majority of patients still receive the inferior 'routine' colonoscopy without CE.
New technology means that the video image obtained during colonoscopy can be digitally enhanced and coloured at the press of a button - termed virtual chromoendoscopy (VCE). This could make surveillance colonoscopy shorter, more comfortable and cleaner (resulting in a more 'dignified' experience) as well as cheaper and less technically difficult.
The main objectives to be explored in this feasibility study (and the larger trial) were informed by a PPI meeting, which placed the ability to detect dysplasia at equal importance with the participant's experience of the procedure in terms of speed, comfort and dignity.
This is primarily a feasibility study to assess patient experience, recruitment and retention rates to the investigators' specified trial design, to support the development of a larger crossover trial to compare VCE to CE during surveillance colonoscopy for colitis.
- Detailed Description
In the recruitment period, 60 patients will be approached when they are invited to attend for scheduled surveillance colonoscopy. Eligible patients (18-75 yrs) who agree to participate will be randomised to undergo CE or VCE as the first procedure. Data will be captured by an Observer using a bespoke Access-based program.
The site and number of any biopsy samples taken will be recorded alongside the Endoscopist's prediction, based on visual appearance, of whether they think the area biopsied is actually dysplasia.
After an agreed interval (no more than 8 weeks, usually 3-6), participants will undergo a second colonoscopy with the second technique, performed by an Endoscopist blinded to the results of the first test, and data captured as before. For each procedure, a questionnaire assessing immediate patient experience will be administered in the Endoscopy department, after the participant has recovered from the procedure. Participants will also be given a second questionnaire assessing their overall experience to take home and complete 48 hours after the procedure, which will be returned by post.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 60
Any patient eligible for colitis surveillance colonoscopy by British Society of Gastroenterology guidelines:
- Ulcerative pan-proctocolitis or Crohn's colitis of 8 or more years duration
- With or without co-diagnosis of primary sclerosing cholangitis
- Inability to provide informed
- Written consent
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Virtual chromoendoscopy Virtual chromoendoscopy Patients will undergo colitis surveillance colonoscopy with FICE(TM) virtual chromoendoscopy Conventional chromoendoscopy Conventional chromoendoscopy Patients will undergo colitis surveillance colonoscopy with indigo carmine chromoendoscopy (dye spray)
- Primary Outcome Measures
Name Time Method Patient adherence to study design - success of recruitment (minimum recruitment of 75%) and retention of patients (minimum target of 75%) 2 years The investigators are evaluating the success of recruitment to the study design with a target minimum recruitment of 75%; The investigators will also evaluate retention of patients within the crossover study design with a minimum target of 75%
- Secondary Outcome Measures
Name Time Method Procedure time 2 years The time taken for each procedure will be compared (average)
Patient experience assessed by validated questionnaire 2 years Patient experience of the procedure in both arms will be compared (intra-individual) by validated questionnaire
Miss rate for dysplasia 2 years The miss rate of each technique will be compared
Prediction of histology 2 years The ability of conventional vs virtual chromoendoscopy will be compared to predict eventual histology of targeted biopsies (from which a sensitivity and specificity will be calculated)
Trial Locations
- Locations (1)
King's College Hospital NHS Foundation Trust
🇬🇧London, United Kingdom